Morgan Stanley Maintains Equal-Weight on Intellia Therapeutics, Raises Price Target to $15

Benzinga Newsdesk www.benzinga.com Positive 72.7%

Neg 0% Neu 0% Pos 72.7%

Morgan Stanley analyst Terence Flynn maintains Intellia Therapeutics (NASDAQ:NTLA) with a Equal-Weight and raises the price target from $11 to $15.